Company Healios K.K.

Equities

4593

JP3835100003

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Healios K.K.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 11:30:00 10/05/2024 am IST			5-day change	1st Jan Change
155 ^JPY	-2.52%		+4.03%	-6.06%

10/04	Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	MT
09/04	Healios K.K. Enters into Joint Research Agreement with AND Medical Group	CI

HEALIOS K.K. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The Company has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Number of employees: 64

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	90	100.0 %	121	100.0 %	+34.44%

JPY in Million	2022	Weight	2023	Weight	Delta
United States 71.3 %	17	18.9 %	87	71.3 %	+411.76%
Japan 26.2 %	63	70.0 %	32	26.2 %	-49.21%
Others 2.5 %	10	11.1 %	3	2.5 %	-70.00%

Managers	Title	Age	Since
Hardy Kagimoto CEO	Chief Executive Officer	47	24/11/24
Richard Kincaid DFI	Director of Finance/CFO	47	01/18/01
Masanori Sawada CTO	Chief Tech/Sci/R&D Officer	42	01/12/01
Kouichi Tamura CTO	Chief Tech/Sci/R&D Officer	67	01/14/01
David W. Smith BRD	Director/Board Member	63	01/18/01
Yoshinari Matsuda BRD	Director/Board Member	45	01/13/01
Jun Narimatsu BRD	Director/Board Member	55	01/13/01

Members of the board	Title	Age	Since
Michael J. Alfant BRD	Director/Board Member	63	01/13/01
Gregory Bonfiglio BRD	Director/Board Member	72	01/18/01
Hardy Kagimoto CEO	Chief Executive Officer	47	24/11/24
Seigo Kashii BRD	Director/Board Member	70	01/17/01
Jun Narimatsu BRD	Director/Board Member	55	01/13/01
Richard Kincaid DFI	Director of Finance/CFO	47	01/18/01
Yoshinari Matsuda BRD	Director/Board Member	45	01/13/01
Kouichi Tamura CTO	Chief Tech/Sci/R&D Officer	67	01/14/01
Masanori Sawada CTO	Chief Tech/Sci/R&D Officer	42	01/12/01
David W. Smith BRD	Director/Board Member	63	01/18/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	90,130,302	56,688,622 ( 62.90 %)	278 ( 0.000308 %)	62.90 %

Name	Equities	%	Valuation
Hardy Kagimoto 31.88 %	28,730,300	31.88 %	31 M ¥
Athos Capital Ltd. 14.98 %	13,503,300	14.98 %	14 M ¥
NIKON CORPORATION 1.706 %	1,537,400	1.706 %	2 M ¥
SUMITOMO PHARMA CO., LTD. 1.664 %	1,500,000	1.664 %	2 M ¥
Oasis Management (Hong Kong) LLC 1.156 %	1,041,700	1.156 %	1 M ¥
Mirabella Financial Services LLP 1.156 %	1,041,700	1.156 %	1 M ¥
Heights Capital Management, Inc. 0.7102 %	640,100	0.7102 %	680 932 ¥
Panview Capital Ltd. 0.6029 %	543,400	0.6029 %	578 063 ¥
Hideki Takeda 0.5592 %	504,000	0.5592 %	536 150 ¥
Maven Investment Partners Ltd. 0.4590 %	413,700	0.4590 %	440 090 ¥

Name	Equities	%	Valuation
ATHERSYS, INC. 1.06%	652,421	1.06%	3,915 $
HEALIOS K.K. 0.00%	200	0.00%	213 $

Healios KK

1-7-1 Yurakucho Chiyoda-Ku

100-0006, Tokyo

http://www.healios.co.jp

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

155 JPY

Average target price

280 JPY

Spread / Average Target

+80.65%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
HEALIOS K.K.	-6.06%	89.62M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs